X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Fresenius Kabi Onco. with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs ACTAVIS (US) - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 FRESENIUS KABI ONCO.   ACTAVIS
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
ACTAVIS
Dec-18
FRESENIUS KABI ONCO./
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs17613,473-   
Low Rs799,038-   
Sales per share (Unadj.) Rs37.73,305.0-  
Earnings per share (Unadj.) Rs5.1-1,064.5-  
Cash flow per share (Unadj.) Rs6.7348.3-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs42.513,631.7-  
Shares outstanding (eoy) m158.23332.60-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.43.4 99.1%   
Avg P/E ratio x25.0-10.6 -236.3%  
P/CF ratio (eoy) x18.932.3 58.6%  
Price / Book Value ratio x3.00.8 362.2%  
Dividend payout %00-   
Avg Mkt Cap Rs m20,1353,743,642 0.5%   
No. of employees `0001.216.9 6.8%   
Total wages/salary Rs m7030-   
Avg. sales/employee Rs Th5,176.265,044.3 8.0%   
Avg. wages/employee Rs Th610.40-   
Avg. net profit/employee Rs Th699.6-20,950.8 -3.3%   
INCOME DATA
Net Sales Rs m5,9631,099,249 0.5%  
Other income Rs m1821,021 0.1%   
Total revenues Rs m5,9811,120,270 0.5%   
Gross profit Rs m1,43028,806 5.0%  
Depreciation Rs m258469,905 0.1%   
Interest Rs m-2663,433 -0.0%   
Profit before tax Rs m1,216-483,511 -0.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-68123,315 -0.1%   
Tax Rs m342-6,127 -5.6%   
Profit after tax Rs m806-354,069 -0.2%  
Gross profit margin %24.02.6 915.2%  
Effective tax rate %28.11.3 2,220.3%   
Net profit margin %13.5-32.2 -42.0%  
BALANCE SHEET DATA
Current assets Rs m5,102450,854 1.1%   
Current liabilities Rs m2,385398,841 0.6%   
Net working cap to sales %45.64.7 962.7%  
Current ratio x2.11.1 189.2%  
Inventory Days Days15020 766.1%  
Debtors Days Days11366 170.9%  
Net fixed assets Rs m5,148124,429 4.1%   
Share capital Rs m1580-   
"Free" reserves Rs m6,5560-   
Net worth Rs m6,7324,533,888 0.1%   
Long term debt Rs m9521,596,546 0.1%   
Total assets Rs m10,3887,087,498 0.1%  
Interest coverage x-45.8-6.6 691.2%   
Debt to equity ratio x0.10.4 40.2%  
Sales to assets ratio x0.60.2 370.1%   
Return on assets %7.5-4.1 -183.1%  
Return on equity %12.0-7.8 -153.3%  
Return on capital %14.6-4.8 -301.7%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Net fx Rs m3,5250-   
CASH FLOW
From Operations Rs m1,274392,720 0.3%  
From Investments Rs m-1,204215,749 -0.6%  
From Financial Activity Rs m-196-674,025 0.0%  
Net Cashflow Rs m-126-65,229 0.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 69.63 Rs / USD

Compare FRESENIUS KABI ONCO. With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare FRESENIUS KABI ONCO. With: STRIDES PHARMA SCIENCE  ABBOTT INDIA  FULFORD INDIA  ORCHID PHARMA LTD  SUVEN LIFESCIENCES  



Today's Market

Sensex Ends 71 Points Lower; Metal and Energy Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their volatile trading day marginally lower.

Related Views On News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

7 Bluechips to Profit from Tech Disruption(Profit Hunter)

Jun 17, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - GSK PHARMA COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS